GSK Share Price, News & Analysis (LON:GSK) GBX 1,430.50 -9.50 (-0.66%) (As of 05:11 PM ET) Add Compare Share Share Today's Range 1,426.80▼ 1,445.8050-Day Range 1,382▼ 1,521.4052-Week Range 1,302.60▼ 1,563.20Volume4.36 million shsAverage Volume6.78 million shsMarket Capitalization£58.65 billionP/E Ratio966.55Dividend Yield3.91%Price TargetGBX 1,566.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability GSK MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside9.5% UpsideGBX 1,566.36 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-1.56Upright™ Environmental ScoreNews Sentiment0.41Based on 5 Articles This WeekInsider TradingAcquiring Shares£832,857 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 stars 2.1 Analyst's Opinion Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,566.36, GSK has a forecasted upside of 9.5% from its current price of GBX 1,430.60.Amount of Analyst CoverageGSK has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GSK. Previous Next 1.7 Dividend Strength Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.00%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 3,783.78%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.Environmental SustainabilityThe Environmental Impact score for GSK is -1.56. Previous Next 1.3 News and Social Media Coverage News SentimentGSK has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GSK this week, compared to 5 articles on an average week.Search InterestOnly 29 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have bought more of their company's stock than they have sold. Specifically, they have bought £8,328.57 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 1.74% of the stock of GSK is held by insiders.Percentage Held by Institutions45.00% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 966.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.28.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 966.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 130.76.Price to Earnings Growth RatioGSK has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GSK Stock (LON:GSK)GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.Read More GSK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSK Stock News HeadlinesDecember 5, 2023 | theglobeandmail.comGSK is a workplace where people can thriveDecember 2, 2023 | finance.yahoo.comBoasting A 52% Return On Equity, Is GSK plc (LON:GSK) A Top Quality Stock?December 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 30, 2023 | msn.comCompetition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine MarketNovember 30, 2023 | msn.comAdaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy INDNovember 30, 2023 | reuters.comGSK CEO says RSV vaccine revenue to top 1 bln pounds in first yearNovember 30, 2023 | theguardian.comNigerians struggle to find medication after GSK pull-outNovember 30, 2023 | americanbankingnews.comCitigroup Reiterates Neutral Rating for GSK (LON:GSK)December 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 28, 2023 | thetimes.co.ukTrial success injects more confidence for GSK blood cancer treatmentNovember 27, 2023 | msn.comGSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head StudyNovember 27, 2023 | msn.comGSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 DataNovember 27, 2023 | americanbankingnews.comGSK (LON:GSK) Receives Buy Rating from Berenberg BankNovember 22, 2023 | msn.comGSK makes first shipment of malaria vaccine to Africa: reportNovember 22, 2023 | msn.comBRIEF-Gsk Will Start Phase III Trials Of Low Carbon Version Of Its Metered Dose Inhaler, Ventolin (Salbutamol) In 2024November 21, 2023 | msn.comGSK plans low-carbon asthma inhaler in bid to cut its greenhouse gas emissionsNovember 21, 2023 | msn.comGSK plans low-carbon asthma inhaler in bid to cut emissionsNovember 21, 2023 | lse.co.ukGSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024November 9, 2023 | forbes.comGSK Buy Write Is Prescription For Quick DividendNovember 8, 2023 | msn.comGSK: Shareholders express concerns over N1.274bn unclaimed dividendsNovember 3, 2023 | finance.yahoo.comGSK outpaces Pfizer in RSV vaccine marketNovember 1, 2023 | morningstar.comTrending: GSK's 3Q Profits Drive Full-Year Guidance Hike, Despite Missing Market ViewsNovember 1, 2023 | uk.movies.yahoo.comIf I’d put £1,000 in GSK shares 1 year ago, here’s what I’d have todayNovember 1, 2023 | finance.yahoo.comGSK (GSK) Q3 Earnings and Revenues Surpass EstimatesNovember 1, 2023 | msn.comGSK to pay $1 billion for exclusive license to J&J's hepatitis B therapyOctober 31, 2023 | msn.comGSK Reports Earnings Wednesday. Here’s What to Expect.October 31, 2023 | msn.comUPDATE 2-GSK's cancer drug Jemperli meets overall survival goal in late-stage trialSee More Headlines Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2020Ex-Dividend for 10/12 Dividend8/17/2023Dividend Payable10/12/2023Ex-Dividend for 1/11 Dividend11/16/2023Today12/07/2023Dividend Payable1/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers - General Sub-IndustryN/A SectorMedical Current SymbolLON:GSK CUSIPN/A CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees69,400Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,566.36 High Stock Price TargetGBX 2,000 Low Stock Price TargetGBX 1,245 Potential Upside/Downside+8.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 1.48 Trailing P/E Ratio972.97 Forward P/E Ratio9.01 P/E Growth0.94Net Income£6.08 billion Net Margins20.48% Pretax MarginN/A Return on Equity61.26% Return on Assets7.90% Debt Debt-to-Equity Ratio165.16 Current Ratio0.95 Quick Ratio0.73 Sales & Book Value Annual Sales£29.65 billion Price / Sales1.99 Cash FlowGBX 176.79 per share Price / Cash Flow8.15 Book ValueGBX 324 per share Price / Book4.44Miscellaneous Outstanding Shares4,100,000,000Free FloatN/AMarket Cap£59.04 billion OptionableNot Optionable Beta0.29 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Emma Natasha Walmsley (Age 53)CEO & Director Comp: $4.79MMs. Julie Belita Brown (Age 61)CFO & Executive Director Ms. Shobie RamakrishnanChief Digital & Technology OfficerMr. Tony WoodChief Scientific OfficerMs. Sarah Elton-FarrHead of Investor RelationsMr. James FordSenior VP & Group General Counsel of Legal & ComplianceMs. Sally JacksonSenior Vice President of Global Communications & CEO OfficeMr. David Simon Redfern BSc (Hons) (Age 57)CA, President of Corporate Development Ms. Diana ConradChief People OfficerMr. Philip C. ThomsonPresident of Global AffairsMore ExecutivesKey CompetitorsAstraZenecaLON:AZNHaleonLON:HLNDechra PharmaceuticalsLON:DPHSmith & NephewLON:SNConvaTec GroupLON:CTECView All CompetitorsInsidersHal BarronBought 219 shares on 9/20/2023Total: £832,857.00 ($3,803.00/share)Hal BarronSold 19,446 sharesTotal: £67.32 M ($3,462.00/share)Emma WalmsleyBought 9 shares on 8/9/2023Total: £12,384.00 ($1,376.00/share)Emma WalmsleyBought 9 shares on 7/11/2023Total: £11,763.00 ($1,307.00/share)Jonathan SymondsBought 6,000 shares on 6/23/2023Total: £8.64 M ($1,440.00/share)View All Insider Transactions Should I Buy GSK Stock? GSK Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Monday, November 27, 2023 at 10:16 AM. Pros Here are some ways that investors could benefit from investing in GSK plc: GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines and specialty medicines to prevent and treat various diseases. This positions the company in a crucial and high-demand sector, offering potential for long-term growth. GSK plc has a strong track record of innovation and a robust pipeline of new products. This indicates the potential for future revenue growth and expansion into new markets. The company has a global presence and operates in multiple countries. This diversification helps mitigate risks associated with regional economic fluctuations and regulatory changes. GSK plc has a history of paying dividends to its shareholders. This can provide a steady income stream for investors, especially those seeking income-oriented investments. Recent developments and advancements in GSK plc's research and development efforts have shown promising results, indicating the potential for breakthrough treatments and therapies in the future. Cons Investors should be bearish about investing in GSK plc for these reasons: GSK plc faces intense competition in the pharmaceutical industry. This competition can impact market share and pricing power, potentially affecting the company's profitability. The company's financial performance may be influenced by factors such as changes in healthcare policies, regulatory approvals, and patent expirations. These external factors can introduce uncertainties and impact the company's revenue and profitability. GSK plc has experienced challenges in the past related to legal and regulatory issues. These issues can result in reputational damage and financial penalties, which may negatively impact the company's stock performance. The stock price of GSK plc is subject to market volatility and fluctuations. Investors should carefully consider their risk tolerance and investment horizon before investing in the company. Investing in the pharmaceutical industry carries inherent risks, including the potential for clinical trial failures, regulatory hurdles, and market uncertainties. Investors should conduct thorough research and analysis before making investment decisions. GSK Stock Analysis - Frequently Asked Questions Should I buy or sell GSK stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks. What is GSK's stock price target for 2024? 8 analysts have issued 12-month price targets for GSK's shares. Their GSK share price targets range from GBX 1,245 to GBX 2,000. On average, they expect the company's share price to reach GBX 1,566.36 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View analysts price targets for GSK or view top-rated stocks among Wall Street analysts. How have GSK shares performed in 2023? GSK's stock was trading at GBX 1,437.60 on January 1st, 2023. Since then, GSK shares have decreased by 0.5% and is now trading at GBX 1,430.60. View the best growth stocks for 2023 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $56.90 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 61.26% and a net margin of 20.48%. How often does GSK pay dividends? What is the dividend yield for GSK? GSK announced a dividend on Wednesday, November 1st. Stockholders of record on Thursday, November 16th will be given a dividend of GBX 14 per share on Thursday, January 11th. This represents a dividend yield of 0.96%. The ex-dividend date is Thursday, November 16th. The official announcement can be viewed at this link. Read our dividend analysis for GSK. Is GSK a good dividend stock? GSK (LON:GSK) pays an annual dividend of GBX 56 per share and currently has a dividend yield of 4.00%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,783.78%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GSK. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD). How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:GSK) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.